News | August 06, 2013

Vanderbilt Heart Participates in Study of New Rapid Cooling Technology to Reduce Heart Damage

Investigational study of Velomedix is for patients with acute myocardial infractions

August 6, 2013 — Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study to assess the safety and feasibility of a rapid cooling system for heart attack patients that could minimize damage to the heart.

Vanderbilt is one of six sites in the United States and Canada, and it is the only one in Tennessee, to offer this study of the Velomedix rapid therapeutic hypothermia system in patients with acute myocardial infarctions (AMIs, also known as heart attacks).

Vanderbilt Heart has already enrolled two patients in this investigational study, which will include up yo 60 patients with a severe form of AMI, called ST-segment elevation myocardial infarction (STEMI). Participants in the study are randomized to one of two arms. Patients in the control arm receive the current standard treatment for STEMI, namely percutaneous coronary intervention (PCI) without therapeutic hypothermia. During this treatment, the physician reopens the blocked blood vessel and returns blood flow to the affected region.

Patients in the treatment arm are rapidly cooled first to a temperature of less than 35°C (95°F) just before receiving the same PCI treatment. The Velomedix system circulates cold fluid throughout the patient’s body to achieve the lower temperature.

To be considered for the study, potential candidates must meet the following criteria:

  • Must be 18 to 85 years of age
  • Having STEMI (? 2mm)
  • Arrive at Vanderbilt within six hours of the start of symptoms
  • Have no previous myocardial infarction
  • Currently not be on dialysis treatment
  • Able to undergo magnetic resonance imaging (MRI) scans
  • Must be willing to return for a follow-up exam including a second MRI scan approximately 30 days after initial treatment

“In three previous studies, we have seen that if a patient is cooled to below 35°C prior to reopening the blocked coronary artery, the size of the heart attack may be reduced substantially,” said Gregg Stone, M.D., of Columbia University Medical Center / New York-Presbyterian Hospital and co-principal investigator of the VELOCITY study. “The cooling approach in this study may prove to be effective in cooling patients fast enough to provide benefit without significantly delaying reperfusion.”

For more information:

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init